Cross-sectional Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Between 18 and 64 Years Old Using the Vaccinees Perception of Injection

Study on Patient Experiences After Receiving the RIV3 Vaccine

Not Recruiting
18 years - 64 years
All
Phase N/A
447 participants needed

Study Overview

This study aims to assess patient-reported experiences post-vaccination with RIV3 using the VAPI instrument, identify drivers for vaccine choice in each case, and assess the cross-validity of VAPI, by establishing magnitude of correlations to EQ-5D-5L domains.

As a feasibility endpoint, this study aims to describe the socio-demographic differences and feasibility of matching between recipients of RIV3 vaccine and mRNA vaccines for COVID-19.

Study Details

This study will be conducted through an online survey that respondents will complete only if they meet the inclusion criteria and give their consent to continue to the main questionnaire. Each participant will complete the survey only once. Participants will provide details about their demographic data, health status, perceptions of flu vaccination and injection site reactions, as well as drivers for vaccine choice and future vaccine use.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Influenza Immunization, Health Volunteers
  • Age: 18 years - 64 years
  • Gender: All

Inclusion Criteria:

  • Be aged 18-64 years old
  • 50 to 64 years will be the main age group for recruitment
  • 18 to 49 years will allow flexibility to face potential recruitment challenges
  • Have received a RIV3 vaccine within the last 2 months
  • Be able to provide explicit consent to participate in the study
  • Reside in continental US (Puerto Rico is excluded)
  • Communicate and read fluently in English (US)
  • Be physically able to participate in a 30 min online survey using an internet-enabled computer or other device (such as a tablet or smartphone)

Exclusion Criteria:

  • Inability to participate in survey
  • Receipt of any other vaccine outside those pre-specified within the past three weeks, and including concomitant vaccination
  • Receipt of co-administered vaccination

Updated on 25 Mar 2025. Study ID: NCT06765187

This study investigates patient-reported experiences after receiving an investigational vaccine. It aims to understand why people choose certain vaccines and how these choices relate to their overall health. The study will also compare the experiences of those who received different types of vaccines for COVID-19, focusing on the differences between these groups.

Participants will take part in an online survey, which they will complete once. The survey will collect information about their demographics, health status, thoughts on flu vaccination, any reactions at the injection site, and reasons for choosing a particular vaccine. The study will use this data to explore the feasibility of matching different vaccine recipients based on socio-demographic factors.

  • Who can participate: Adults aged 18 to 64 who have received the RIV3 vaccine in the last two months and live in the continental US can participate. Participants must be able to consent, communicate in English, and complete a 30-minute online survey. Exclusion criteria include having received other vaccines recently.
  • Study details: Participants will complete a one-time online survey about their vaccination experience. The survey will gather information on demographics, health, and vaccine perceptions.